4G Clinical Launches Innovative 4C Supply Software
4G Clinical has announced the launch of 4C Supply, a clinical supply optimization software powered by Natural Language Processing (NLP). The new product addresses the increased pressures on clinical supply professionals to continuously adapt to new trial information as protocol complexity continues to rise.
Clinical supply professionals are tasked with assessing the impact of protocol revisions, sometimes as soon as the initial protocol version is approved. Supply impact assessments are critical, and time sensitive, and traditional supply software solutions are slow to respond and challenging to interpret without extensive knowledge of statistical algorithms.
4C Supply utilizes Natural Language Processing (NLP) to turn study parameters from plain English into detailed forecasts, allowing supply managers to modify supply models as frequently as needed without effort, with full transparency into inputs and a direct correlation to its outputs.
"Over the past year, 4G Clinical has collaborated with bio/pharma clinical supply professionals to verify the industry need for an improved solution and pressure test the development of 4C Supply," says Jan Pieter Kappelle, Vice President of Strategy at 4G Clinical. "We have been incredibly fortunate to have such a dedicated group of advisors and we are excited to announce the launch of what we believe is a game-changer for clinical supply professionals."
"To be involved in the creation of an innovative clinical supply software solution from the onset has been a valued opportunity for us," says Darrin Sloan, Senior Manager, Clinical Supply at Eisai. "We are excited for the commercial launch of 4C Supply and the benefit it will bring to supply managers across the industry."
In addition to early collaborators, 4G Clinical has also extended early access to 4C Supply to several of their Prancer RTSM customers.
"4G Clinical's RTSM has completely changed the way we have built studies and managed our supplies," says Karen McNamara, Senior Director, Product Development at Infinity Pharmaceuticals. "We are incredibly excited to be an early-adopter of 4C Supply and look forward to our continued partnership with 4G Clinical."
"The launch of 4C Supply is a testament to 4G Clinical's commitment to accelerating clinical trials," says David Kelleher, CEO of 4G Clinical. "Managing the complexity of clinical supply in a more efficient and intuitive manner better enables patients to receive the right medication at exactly the right time."
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
